Cyclacel Pharmaceuticals Stock (NASDAQ: CYCC)

Cyclacel Pharmaceuticals Stock (NASDAQ:CYCC), Trade Ideas

Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib, Sapacitabine, and plogosertib.

Caterpillar - logo

ACON

AIRE

ATNI

BMRN

BNAI

BPTS

BRFH

BRKL

CDTX

CSSE

CYCC

ESGL

FCFS

HRYU

HUIZ

ILAG

JAKK

OPTN

ORGO

PCSA

POAI

PTSI

SGBX

SNBR

SPCB

STRA

ULBI

ZAPP

Why Caterpillar Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday&#39;s Mid-Day Session

News

Penny Stocks

Pre-Market Outlook

Markets

Movers

Trading Ideas

ARBB

BETS

CLDI

CNEY

GOEV

GRFS

GRTX

JNPR

MGOL

NTBL

SNGX

SPEC

SYRA

TCJH

VINC

ZCAR

Shares of  Juniper Networks, Inc. (NYSE: JNPR) rose sharply in pre-market trading on Tuesday.

Why Juniper Networks Shares Are Trading Higher By Over 23%; Here Are 20 Stocks Moving Premarket

Small Cap

Intraday Update

AMAM

AMPE

ARBK

ARDX

AREN

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

AXNX

BCRX

BFLY

BNZI

BSGM

CROX

DADA

DVAX

ELEV

FSLY

HARP

LMDX

NEXI

NKTX

PACB

PRAX

PRTA

RGNX

RVNC

RXST

SHPH

SILK

SNMP

STSS

STTK

TREE

UPWK

VERO

ZJYL

Shares of  RxSight, Inc. (NASDAQ: RXST) rose sharply during Monday’s session after the company issued preliminary FY23 and FY24 revenue guidance above estimates.

Also, Needham maintained a Buy rating on the stock and raised its price target from $35 to $41.

Why RxSight Shares Are Trading Higher By 20%? Here Are Other Stocks Moving In Monday&#39;s Mid-Day Session

Cyclacel Pharmaceuticals, Inc. - Common Stock

Cyclacel Pharmaceuticals Inc

Cyclacel Pharmaceuticals, Inc. - 6% Convertible Preferred Stock

Shares of Caterpillar Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAT#NYSE">CAT</a>) fell sharply during Thursday's session after the company reported better-than-expected first-quarter EPS but missed <a href="https://www.benzinga.com/news/earnings/24/04/38433251/why-is-equipment-giant-caterpillar-stock-plunging-today">revenue estimates</a>.
Caterpillar reported a first-quarter fiscal 2024 revenue of $15.8 billion, a slight decrease of 0.4% year-over-year, missing the consensus of $16.216 billion. CAT's adjusted earnings of $5.60 per share, compared to $4.91 a year ago, topped the consensus of $5.14, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Caterpillar shares dipped 6.6% to $339.37 on Thursday.
Here are some other stocks moving in today&#8217;s mid-day session.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Barfresh Food Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRFH#NASDAQ">BRFH</a>) surged 87.2% to $2.05.</li>
<li>Safe &amp; Green Holdings Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGBX#NASDAQ">SGBX</a>) shares jumped 80% to $0.26. Safe &amp; Green Holdings said it has entered into an agreement to produce 4 modular electrical distribution centers as part of a multi-unit order for a client serving the big box retailer market.</li>
<li>Processa Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCSA#NASDAQ">PCSA</a>) shares gained 37.2% to $2.2250 after HC Wainwright &amp; Co initiated coverage on the stock with a Buy rating and announced an $8 price target.</li>
<li>Aclarion, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACON#NASDAQ">ACON</a>) rose 35% to $0.3899.</li>
<li>reAlpha Tech Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRE#NASDAQ">AIRE</a>) gained 28.5% to $1.4906 after jumping 93% on Wednesday.</li>
<li>OptiNose, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPTN#NASDAQ">OPTN</a>) rose 27.5% to $1.1806 after the company issued corporate updates, expecting to produce positive income from operations for the full year 2025.</li>
<li>Intelligent Living Application Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILAG#NASDAQ">ILAG</a>) shares climbed 21.3% to $0.6550 after gaining over 12% on Wednesday.</li>
<li>P.A.M. Transportation Services, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTSI#NASDAQ">PTSI</a>) surged 19.8% to $17.42 after the company announced a self-tender offer to purchase up to 550,000 shares at a price not less than $15.50-$18.00 per share.</li>
<li>SuperCom Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPCB#NASDAQ">SPCB</a>) climbed 19% to $0.2663. SuperCom received over $5 million in new orders from European Governments.</li>
<li>Ultralife Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULBI#NASDAQ">ULBI</a>) climbed 16.6% to $10.19 after the company reported better-than-expected quarterly financial results.</li>
<li>Impinj, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PI#NASDAQ">PI</a>) gained 16% to $140.21 after reporting better-than-expected first-quarter financial results.</li>
<li>Cidara Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) gained 13.9% to $14.00 after the company announced the divestiture of rezafungin to Mundipharma, reacquired global development and commercial rights to CD388 and announced $240 million in private placement financing.</li>
<li>Sleep Number Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNBR#NASDAQ">SNBR</a>) surged 11.5% to $15.13 following first-quarter results.</li>
<li>Predictive Oncology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POAI#NASDAQ">POAI</a>) rose 10.7% to $1.49. Fujifilm and Predictive Oncology announced collaboration to reduce protein interference in bacterial endotoxin detection testing of biopharmaceuticals.</li>
<li>Strategic Education, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRA#NASDAQ">STRA</a>) jumped 10% to $110.78 following upbeat results.</li>
<li>Tyler Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TYL#NYSE">TYL</a>) gained 9.6% to $459.39 after the company reported better-than-expected first-quarter EPS and sales. Additionally, the company provided upbeat guidance for FY24.</li>
<li>TransUnion (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRU#NYSE">TRU</a>) climbed 8.9% to $74.83 after the company reported better-than-expected first-quarter financial results. The company also provided upbeat guidance for second quarter</li>
<li>AstraZeneca PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NYSE">AZN</a>) rose 5.8% to $75.35 following a first-quarter revenue beat.</li>
<li>Teradyne, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TER#NYSE">TER</a>) gained 5% to $105.71 after the company posted upbeat first-quarter results and issued strong second-quarter forecast.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>E-Home Household Service Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EJH#NASDAQ">EJH</a>) shares dipped 75% to $0.7192.</li>
<li>Chicken Soup for the Soul Entertainment, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSSE#NASDAQ">CSSE</a>) fell 39.3% to $0.2581. Chicken Soup For The Soul Entertainment received delinquency letter from the Nasdaq.</li>
<li>Hanryu Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRYU#NASDAQ">HRYU</a>) shares dropped 37% to $0.3330. Hanryu Holdings received delinquency notice from the Nasdaq for late annual report filing.</li>
<li>ATN International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATNI#NASDAQ">ATNI</a>) fell 29% to $20.39 as the company posted weak quarterly sales and slashed FY24 revenue forecast.</li>
<li>Brand Engagement Network, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNAI#NASDAQ">BNAI</a>) fell 27.3% to $2.71.</li>
<li>Huize Holding Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUIZ#NASDAQ">HUIZ</a>) shares dipped 26% to $0.39.</li>
<li>Cyclacel Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) fell 24% to $1.7283.</li>
<li>Hertz Global Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTZ#NASDAQ">HTZ</a>) dipped 23% to $4.4299 after the company mixed first-quarter financial results.</li>
<li>Organogenesis Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORGO#NASDAQ">ORGO</a>) fell 17.8% to $2.44</li>
<li>Orion Group Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORN#NYSE">ORN</a>) fell 17% to $6.60 following weak quarterly sales.</li>
<li>JAKKS Pacific, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAKK#NASDAQ">JAKK</a>) fell 16.4% to $19.58 following a wider-than-expected quarterly loss.</li>
<li>Zapp Electric Vehicles Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZAPP#NASDAQ">ZAPP</a>) fell 16.4% to $3.3001 after dipping 15% on Wednesday.</li>
<li>Brookline Bancorp, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKL#NASDAQ">BRKL</a>) dipped 13.8% to $8.23 following downbeat quarterly results.</li>
<li>Ethan Allen Interiors Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETD#NYSE">ETD</a>) fell 13.5% to $28.91 following downbeat quarterly results.</li>
<li>MarineMax, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HZO#NYSE">HZO</a>) shares fell 13.5% to $23.50 after the company posted downbeat quarterly results and slashed FY24 EPS guidance.</li>
<li>ESGL Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESGL#NASDAQ">ESGL</a>) shares fell 12.9% to $0.5499.</li>
<li>Harley-Davidson, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HOG#NYSE">HOG</a>) declined 12.7% to $34.45 following first-quarter results.</li>
<li>Meta Platforms, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) shares declined 11.3% to $437.50 after reporting first-quarter results.</li>
<li>Biophytis S.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPTS#NASDAQ">BPTS</a>) fell 9.7% to $8.57. Biophytis announced transfer of ADSs to OTC Market.</li>
<li>International Business Machines Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>) fell 8.6% to $168.24 after the company reported mixed first-quarter financial results. The company also announced it will acquire HashiCorp.</li>
<li>Textron Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TXT#NYSE">TXT</a>) shares fell 12% to $82.78 following weaker-than-expected quarterly earnings.</li>
<li>FirstCash Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCFS#NASDAQ">FCFS</a>) dipped 10.6% to $118.00 following weak quarterly sales.</li>
<li>Whirlpool Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WHR#NYSE">WHR</a>) fell 9.2% to $95.98 following first-quarter results.</li>
<li>BioMarin Pharmaceutical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) dipped 9% to $83.05 after the company reported first-quarter financial results.</li>
<li>Reliance, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RS#NYSE">RS</a>) fell 8.8% to $285.73 after the company reported worse-than-expected first-quarter financial results.</li>
<li>AZZ Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZZ#NYSE">AZZ</a>) dipped 8.6% to $75.28. AZZ announced a proposed public offering of 4 million shares of common stock.</li>
<li>Southwest Airlines Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUV#NYSE">LUV</a>) shares declined 7.7% to $27.03 after the company reported worse-than-expected first-quarter financial results.</li>
<li>Bristol-Myers Squibb Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) fell 6.8% to $45.50 following first-quarter earnings.</li>
<li>ServiceNow, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>) shares fell 5.6% to $704.40 after the company reported first-quarter financial results.</li>
<li>Graco Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GGG#NYSE">GGG</a>) shares slipped 5.2% to $84.67 following downbeat first-quarter results.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/news/24/04/38430578/top-3-financial-stocks-that-could-sink-your-portfolio-this-quarter">Top 3 Financial Stocks That Could Sink Your Portfolio This Quarter</a>

Why Caterpillar Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

<h3>Gainers</h3>
<ul>
<li>Aclarion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACON#NASDAQ">ACON</a>) shares moved upwards by 66.7% to $0.48 during Thursday's regular session. The market value of their outstanding shares is at $3.4 million. </li>
<li>Processa Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCSA#NASDAQ">PCSA</a>) stock moved upwards by 43.18% to $2.32. The market value of their outstanding shares is at $6.6 million. </li>
<li>Akso Health Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AHG#NASDAQ">AHG</a>) shares moved upwards by 29.87% to $1.0. The market value of their outstanding shares is at $109.5 million. </li>
<li>Eyenovia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) shares increased by 22.87% to $0.72. The company's market cap stands at $33.9 million. </li>
<li>Predictive Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POAI#NASDAQ">POAI</a>) stock increased by 21.64% to $1.63. The company's market cap stands at $6.6 million. </li>
<li>IMAC Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BACK#NASDAQ">BACK</a>) shares moved upwards by 18.93% to $4.14. The market value of their outstanding shares is at $4.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) stock declined by 33.1% to $1.54 during Thursday's regular session. The market value of their outstanding shares is at $2.0 million. </li>
<li>Organogenesis Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORGO#NASDAQ">ORGO</a>) stock decreased by 22.32% to $2.31. The market value of their outstanding shares is at $305.4 million. </li>
<li>Xylo Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XYLO#NASDAQ">XYLO</a>) shares decreased by 16.35% to $1.74. The market value of their outstanding shares is at $3.2 million. </li>
<li>Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) stock declined by 14.31% to $1.4. The market value of their outstanding shares is at $6.2 million. </li>
<li>American Oncology Network (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AONC#NASDAQ">AONC</a>) shares fell 14.14% to $3.95. The company's market cap stands at $41.8 million. </li>
<li>INVO Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INVO#NASDAQ">INVO</a>) shares decreased by 13.68% to $1.01. The market value of their outstanding shares is at $2.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AONC

BACK

EYEN

INVO

PTIX

XYLO

12 Health Care Stocks Moving In Thursday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>Processa Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCSA#NASDAQ">PCSA</a>) shares moved upwards by 31.2% to $2.12 during Thursday's pre-market session. The company's market cap stands at $6.0 million. </li>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) stock rose 23.04% to $2.83. The company's market cap stands at $3.7 million. </li>
<li>Compass Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPX#NASDAQ">CMPX</a>) shares rose 21.62% to $1.8. The market value of their outstanding shares is at $247.6 million. </li>
<li>Virax Biolabs Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRAX#NASDAQ">VRAX</a>) shares increased by 19.37% to $0.79. The company's market cap stands at $1.8 million. </li>
<li>Nuwellis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) shares increased by 13.84% to $0.29. The company's market cap stands at $1.9 million. </li>
<li>Can Fite Biofarma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CANF#AMEX">CANF</a>) stock moved upwards by 12.37% to $2.18. The company's market cap stands at $10.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Sunshine Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBFM#NASDAQ">SBFM</a>) stock decreased by 10.5% to $0.83 during Thursday's pre-market session. </li>
<li>Vaccinex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCNX#NASDAQ">VCNX</a>) shares declined by 8.1% to $4.6. The company's market cap stands at $7.2 million. </li>
<li>SenesTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNES#NASDAQ">SNES</a>) stock fell 8.04% to $0.7. The company's market cap stands at $3.6 million. </li>
<li>Pluri (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLUR#NASDAQ">PLUR</a>) stock decreased by 7.27% to $4.72. The company's market cap stands at $24.6 million. </li>
<li>Adial Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADIL#NASDAQ">ADIL</a>) stock fell 7.02% to $1.59. The market value of their outstanding shares is at $6.4 million. </li>
<li>Heart Test Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSCS#NASDAQ">HSCS</a>) shares declined by 6.86% to $0.1. The market value of their outstanding shares is at $6.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADIL

CANF

CMPX

HSCS

NUWE

PLUR

SBFM

SNES

VCNX

VRAX

12 Health Care Stocks Moving In Thursday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Clene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLNN#NASDAQ">CLNN</a>) shares moved upwards by 54.9% to $0.48 during Tuesday's after-market session. The company's market cap stands at $61.6 million. </li>
<li>Talphera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLPH#NASDAQ">TLPH</a>) shares moved upwards by 11.65% to $1.15. The company's market cap stands at $19.5 million. </li>
<li>Lexaria Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LEXX#NASDAQ">LEXX</a>) stock moved upwards by 8.22% to $2.5. The market value of their outstanding shares is at $32.2 million. </li>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) stock increased by 7.14% to $1.8. The market value of their outstanding shares is at $2.3 million. </li>
<li>IGC Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IGC#AMEX">IGC</a>) shares rose 6.99% to $0.52. The company's market cap stands at $34.3 million. </li>
<li>SHL Telemedicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHLT#NASDAQ">SHLT</a>) stock increased by 6.94% to $5.39. The market value of their outstanding shares is at $88.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Telesis Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBIO#NASDAQ">TBIO</a>) shares fell 15.9% to $0.31 during Tuesday's after-market session. The company's market cap stands at $9.2 million. </li>
<li>Dynatronics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYNT#NASDAQ">DYNT</a>) stock decreased by 14.53% to $0.47. The market value of their outstanding shares is at $2.2 million. </li>
<li>Ontrak (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OTRK#NASDAQ">OTRK</a>) stock decreased by 13.29% to $0.4. The market value of their outstanding shares is at $16.9 million. As per the news, the Q4 earnings report came out today. </li>
<li>China SXT Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTC#NASDAQ">SXTC</a>) stock fell 12.35% to $1.42. </li>
<li>PaxMedica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PXMD#NASDAQ">PXMD</a>) shares fell 9.75% to $0.6. The market value of their outstanding shares is at $4.4 million. </li>
<li>Longeveron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGVN#NASDAQ">LGVN</a>) stock declined by 9.35% to $3.2. The company's market cap stands at $10.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CLNN

DYNT

LEXX

LGVN

OTRK

PXMD

SHLT

SXTC

TBIO

TLPH

12 Health Care Stocks Moving In Tuesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Eliem Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELYM#NASDAQ">ELYM</a>) stock moved upwards by 51.6% to $4.05 during Thursday's pre-market session. The market value of their outstanding shares is at $112.2 million. </li>
<li>Rallybio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLYB#NASDAQ">RLYB</a>) stock increased by 49.07% to $2.43. The company's market cap stands at $91.8 million. </li>
<li>Alpine Immune Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALPN#NASDAQ">ALPN</a>) shares rose 36.62% to $64.27. The company's market cap stands at $4.2 billion. </li>
<li>IMAC Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BACK#NASDAQ">BACK</a>) stock increased by 22.41% to $3.44. The market value of their outstanding shares is at $3.9 million. </li>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) shares rose 15.3% to $1.77. The market value of their outstanding shares is at $8.2 million. </li>
<li>Lipocine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPCN#NASDAQ">LPCN</a>) stock rose 15.2% to $7.5. The market value of their outstanding shares is at $39.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Aptevo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APVO#NASDAQ">APVO</a>) stock declined by 55.0% to $1.08 during Thursday's pre-market session. </li>
<li>SILO Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SILO#NASDAQ">SILO</a>) shares fell 13.34% to $1.82. The company's market cap stands at $5.1 million. </li>
<li>Acorda Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACOR#NASDAQ">ACOR</a>) shares decreased by 10.96% to $0.78. </li>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) shares decreased by 10.25% to $1.84. The market value of their outstanding shares is at $2.4 million. </li>
<li>AVITA Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCEL#NASDAQ">RCEL</a>) shares decreased by 9.98% to $13.0. The company's market cap stands at $334.1 million. </li>
<li>Scinai Immunotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCNI#NASDAQ">SCNI</a>) stock declined by 9.79% to $0.44. The market value of their outstanding shares is at $1.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACOR

ALPN

APVO

ELYM

HCTI

LPCN

RCEL

RLYB

SCNI

SILO

- New clinical, PK and PD data from novel CDK2/9 inhibitor fadraciclib monotherapy studies support ongoing development program in patients with solid tumors and lymphoma -
BERKELEY HEIGHTS, N.J., April 01, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>, NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCCP#NASDAQ">CYCCP</a>, ", Cyclacel", or the ", Company", )))), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that new clinical, pharmacokinetic (PK) and pharmacodynamic (PD) data from the CYC065-101 study of fadraciclib as monotherapy was selected by the Scientific Program Committee for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting from May 31-June 4, 2024 in Chicago.
Details of the presentations are as follows:
<figure class="table"> 
<table>
<tbody>
<tr>
<td>Title:</td>
<td>A phase 1 study evaluating the safety, pharmacokinetics, and efficacy of fadraciclib, an oral CDK2/9 inhibitor, in patients with advanced solid tumors and lymphoma</td>
</tr>
<tr>
<td>Abstract No.&nbsp;for Publication:</td>
<td>3125</td>
</tr>
<tr>
<td>Session Title:</td>
<td>Poster Session – Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology</td>
</tr>
<tr>
<td>Date and Time:</td>
<td>June 1, 2024, 9:00 AM - 12:00 PM CDT</td>
</tr>
</tbody>
</table>
</figure>
About Cyclin-Dependent Kinases and Fadraciclib Cyclin-dependent kinases (CDKs) are critical for cell cycle control and transcriptional regulation. Dysregulated CDKs have been linked to the cancer hallmarks of uncontrolled proliferation and increased cancer cell survival. Fadraciclib is a highly selective, potent, orally and intravenously available, next generation inhibitor of CDK2 and CDK9. By inhibiting CDK2 and CDK9 fadraciclib causes apoptotic death through anaphase catastrophe of cancer cells at sub-micromolar concentrations.
To date single agent activity, including CR, PR and SD, has been observed in patients with advanced endometrial, squamous NSCLC lung cancer and T-cell lymphoma. Encouraging signals of activity were observed in patients with advanced cervical, hepatocellular, ovarian and pancreatic cancers.
065-101 Study of Oral Fadraciclib
Oral fadraciclib is being tested in a Phase 1/2 trial for the treatment of advanced solid tumors and lymphoma (065-101; <a href="https://www.globenewswire.com/Tracker?data=4O9UTRrc_Lbh9aVJZibg9hr-bEAnUq1rMw_QgFENmv1aR4VmOd1JEAADCHy5GVA57FjhIP8ytpq9VBdOJnh0gqbuqO9sMzavFqHKzgQ4BVFeDjmcfXwqo9-8p4Vvx-pRPDXMe8dCRlkiB7BODij9OeXGV_lyMdGUtKVFjjC0DtM=">NCT#04983810</a>). A total of 47 patients have been treated as monotherapy in this ongoing study. The study is enrolling unselected, all comer patients with advanced solid tumors and lymphoma.
The Phase 2 part of the 065-101 study is designed to further evaluate fadra safety and efficacy in up to 8 cohorts defined by histology and/or NGS. The study is powered to demonstrate response in the molecular subtype suggested by the Phase 1 data and others that may be sensitive.
CDKN2A, CDKN2B deletions
CDKN2A gene deletions occur in over 10% of several solid tumors, including glioma, head and neck, pancreatic, esophageal, lung (incl. squamous), bladder, hepatobiliary, breast, melanoma, sarcoma, and others. In addition, CDKN2A deletions have been reported in 46% of patients with PTCL-NOS, a subtype of lymphoma. CDKN2B deletions occur in over 10% of several solid tumors, including bladder, glioma, lung (incl. squamous), head and neck, pancreatic, melanoma, esophageal, sarcoma, hepatobiliary, breast, ovarian and others.

Biotech

General

CYCCP

Cyclacel Pharmaceuticals To Present New Clinical Data At 2024 ASCO Annual Meeting Highlighting Fadraciclib's Potential As A Precision Medicine For Cancer

Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) reported quarterly losses of $(6.23) per share which missed the analyst consensus estimate of $(5.89) by 5.77 percent. This is a 30.78 percent increase over losses of $(9.00) per share from the same period last year. The company reported $31.00 thousand in sales this quarter.

Earnings

Cyclacel Pharmaceuticals Q4 EPS $(6.23) Misses $(5.89) Estimate, Sales $31.00K

<h3>Companies Reporting Before The Bell</h3>
&bull; Tencent Music Enter Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TME#NYSE">TME</a>) is projected to report quarterly earnings at $0.14 per share on revenue of $931.97 million.
&bull; HUYA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUYA#NYSE">HUYA</a>) is likely to report quarterly loss at $0.12 per share on revenue of $210.04 million.
&bull; Caleres (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAL#NYSE">CAL</a>) is expected to report quarterly earnings at $0.85 per share on revenue of $694.33 million.
&bull; XPeng (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>) is likely to report quarterly loss at $0.46 per share on revenue of $1.86 billion.
&bull; Core &amp; Main (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNM#NYSE">CNM</a>) is likely to report quarterly earnings at $0.35 per share on revenue of $1.43 billion.
&bull; Citi Trends (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTRN#NASDAQ">CTRN</a>) is likely to report quarterly earnings at $0.79 per share on revenue of $216.32 million.
&bull; ZKH Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZKH#NYSE">ZKH</a>) is projected to report earnings for its fourth quarter.
<h3>Companies Reporting After The Bell</h3>
&bull; Mitek Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MITK#NASDAQ">MITK</a>) is likely to report earnings for its fourth quarter.
&bull; Orla Mining (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ORLA#AMEX">ORLA</a>) is estimated to report earnings for its fourth quarter.
&bull; Design Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSGN#NASDAQ">DSGN</a>) is estimated to report earnings for its fourth quarter.
&bull; HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) is projected to report quarterly earnings at $0.56 per share on revenue of $258.13 million.
&bull; TeraWulf (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WULF#NASDAQ">WULF</a>) is projected to report quarterly loss at $0.02 per share on revenue of $24.16 million.
&bull; Taysha Gene Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSHA#NASDAQ">TSHA</a>) is likely to report quarterly loss at $0.11 per share on revenue of $2.65 million.
&bull; Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) is expected to report earnings for its fourth quarter.
&bull; Corvus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVS#NASDAQ">CRVS</a>) is estimated to report earnings for its fourth quarter.
&bull; Bridger Aerospace Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BAER#NASDAQ">BAER</a>) is projected to report earnings for its fourth quarter.
&bull; Relmada Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLMD#NASDAQ">RLMD</a>) is likely to report earnings for its fourth quarter.
&bull; ZTO Express (Cayman) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTO#NYSE">ZTO</a>) is expected to report quarterly earnings at $0.37 per share on revenue of $1.52 billion.
&bull; Precigen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGEN#NASDAQ">PGEN</a>) is expected to report quarterly loss at $0.08 per share on revenue of $1.70 million.
&bull; Harrow (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HROW#NASDAQ">HROW</a>) is projected to report quarterly loss at $0.04 per share on revenue of $37.86 million.
This article was generated by Benzinga&#39;s automated content engine and reviewed by an editor.

BAER

CRVS

CTRN

DSGN

HROW

HUYA

MITK

ORLA

PGEN

RLMD

TSHA

WULF

XPEV

Earnings Scheduled For March 19, 2024

Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) is set to give its latest quarterly earnings report on Tuesday, 2024-03-19. Here's what investors need to know before the announcement.
Analysts estimate that Cyclacel Pharmaceuticals will report an earnings per share (EPS) of $-5.89. 
Cyclacel Pharmaceuticals bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Past Earnings Performance</h3>
Last quarter the company missed EPS by $1.95, which was followed by a 35.54% drop in the share price the next day.
Here's a look at Cyclacel Pharmaceuticals's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-5.40</td>
<td>-7.5</td>
<td>-9.90</td>
<td>-7.2</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-7.35</td>
<td>-6.6</td>
<td>-7.05</td>
<td>-9</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-36.0%</td>
<td>-0.0%</td>
<td>-1.0%</td>
<td>-3.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1710774020_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Cyclacel Pharmaceuticals were trading at $2.43 as of March 15. Over the last 52-week period, shares are down 73.11%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/CYCC/earnings">To track all earnings releases for Cyclacel Pharmaceuticals visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Outlook For Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>, NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCCP#NASDAQ">CYCCP</a>, ", Cyclacel", or the ", Company", )))), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that preclinical proof-of-concept data with the Company's fadraciclib will be presented at the upcoming <a href="https://www.globenewswire.com/Tracker?data=KURYcXTAECgTx9KiHdZ8eDDE-hid2XQOrxKUfywrqTnWYTFB-bQBL5oYFrgL43p7M1i-0wXWlTJ51idtMMZlvlIlbRaYgMi1gYRRGKZzHt079gRrPSzUQCze3Qc_WhtdGX_Ts8vGPf0LORISopuC7j3Upr87lFsa4FPBQjnpt-UYYPLzdjbLPqS3MfsmLNIDZXo-4itOETODbC_-aYWkjR8onHSb5Xy4-nRIJTD597KzSC7xjx-X-l0z0jD8MddsV_X0as-lMg40jJnVQgH5asw9zo-6CbXSG14lHPXucxvby7KcAzyl6DrXmH7PqqX1TARd6b4OEpgmdFl9UGFnuhTXau8Cu_4xL4TxUd3d4nBfBSVHZcZ9pgVUs89vkIaiSW3x7vabwp27MKeHFw90Lw==">American Association for Cancer Research (AACR) Annual Meeting 2024,</a> being held&nbsp;April 5-10 in&nbsp;San Diego, California. The data will be presented at three poster sessions and report activity and antitumor effects of fadraciclib in biliary tract cancer, lung cancer, Richter transformation and lymphoma cell lines. &nbsp;
Details of the presentations are as follows:
<figure class="table"> 
<table>
<tbody>
<tr>
<td>Title:</td>
<td>The CDK2/9 inhibitor fadraciclib is active in Richter transformation and lymphoma cell lines by targeting both cell survival and proliferation</td>
</tr>
<tr>
<td>Abstract No:</td>
<td>518 / 15</td>
</tr>
<tr>
<td>Session Topic:</td>
<td><a href="https://www.abstractsonline.com/pp8/#!/20272/session/302">Session PO.ET05.01 - Cell Cycle, Transcription Regulation, and Anticancer Drug Action</a></td>
</tr>
<tr>
<td>Date and Time:</td>
<td>April 7, 2024, 1:30 PM - 5:00 PM PT</td>
</tr>
<tr>
<td>Location:</td>
<td>Exhibition Hall, Section 21</td>
</tr>
</tbody>
</table>
</figure>
&nbsp; &nbsp;
<figure class="table"> 
<table>
<tbody>
<tr>
<td>Title:</td>
<td>Elucidation of the fates of CDK2 inhibited aneuploid and residual lung cancers</td>
</tr>
<tr>
<td>Abstract No:</td>
<td>2117 / 8</td>
</tr>
<tr>
<td>Session Topic:</td>
<td><a href="https://www.abstractsonline.com/pp8/#!/20272/session/311">Session PO.ET07.02 - Pharmacodynamic Biomarkers of Drug Response</a></td>
</tr>
<tr>
<td>Date and Time:</td>
<td>April 8, 2024, 9:00 AM - 12:30 PM PT</td>
</tr>
<tr>
<td>Location:</td>
<td>Exhibition Hall, Section 30</td>
</tr>
</tbody>
</table>
</figure>
&nbsp; &nbsp;
<figure class="table"> 
<table>
<tbody>
<tr>
<td>Title:</td>
<td>Anti-tumor effects of fadraciclib, CDK2/9 inhibitor, in biliary tract cancer</td>
</tr>
<tr>
<td>Abstract No:</td>
<td>5711 / 11</td>
</tr>
<tr>
<td>Session Topic:</td>
<td><a href="https://www.abstractsonline.com/pp8/#!/20272/session/360">Session PO.MCB01.01 - Pharmacologic Targeting of Cell Cycle Proteins</a></td>
</tr>
<tr>
<td>Date and Time:</td>
<td>April 9, 2024, 1:30 PM - 5:00 PM PT</td>
</tr>
<tr>
<td>Location:</td>
<td>Exhibition Hall, Section 18</td>
</tr>
</tbody>
</table>
</figure>
About Cyclin-Dependent Kinases and Fadraciclib Cyclin-dependent kinases (CDKs) are critical for cell cycle control and transcriptional regulation. Dysregulated CDKs have been linked to the cancer hallmarks of uncontrolled proliferation and increased cancer cell survival. Fadraciclib is a highly selective, potent, orally and intravenously available, next generation inhibitor of CDK2 and CDK9. By inhibiting CDK2 and CDK9 fadraciclib causes apoptotic death through anaphase catastrophe of cancer cells at sub-micromolar concentrations.
To date single agent activity, including CR, PR and SD, has been observed in patients with advanced endometrial, squamous NSCLC lung cancer and T-cell lymphoma. Encouraging signals of activity were observed in patients with advanced cervical, hepatocellular, ovarian and pancreatic cancers.
065-101 Study of Oral Fadraciclib
Oral fadraciclib is being tested in a Phase 1/2 trial for the treatment of advanced solid tumors and lymphoma (065-101; <a href="https://www.globenewswire.com/Tracker?data=PR_dAy-w0l89F0_hQ5ePrq-9EMTOk5FR9qwOTqAwGpI8rG5aVCTXHAbwHyvK_NSLQ7B5sfMgj047l192PqRfIo-IByZJU7XvkQl1NpqpiWToCITW3ST7xJOGCxM8zrV-qzmefigQs3H7ADZ4qny7ST-hBSW_-cQ3SLv2V6WnEIo=">NCT#04983810</a>). A total of 29 patients have been treated as monotherapy in this ongoing study. The study is enrolling unselected, all comer patients with advanced solid tumors and lymphoma.
The Phase 2 part of the 065-101 study is designed to further evaluate fadra safety and efficacy in up to 8 cohorts defined by histology and/or NGS. The study is powered to demonstrate response in the molecular subtype suggested by the Phase 1 data and others that may be sensitive.
CDKN2A, CDKN2B, MTAP deletions
CDKN2A gene deletions occur in over 40% of several solid tumors, including glioma, head and neck, pancreatic, esophageal, lung (incl. squamous), bladder, melanoma, and others. CDKN2B deletions occur in over 30% of several solid tumors, including bladder, glioma, pancreatic, esophageal, lung (incl. squamous), head and neck, melanoma, and others. MTAP deletions occur in over 25% of several solid tumors, including glioma, mesothelioma, pancreatic, bladder, esophageal and others. MTAP deletion confers dependency on the PRMT5 enzyme in cancer cells which was identified as a synthetic lethal target for MTAP deleted cancers.

Events

Cyclacel Pharmaceuticals Announces Preclinical Proof-Of-Concept Data For Fadraciclib To Be Presented At The American Association For Cancer Research Annual Meeting 2024

Cyclacel Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>, NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCCP#NASDAQ">CYCCP</a>, ", Cyclacel", or the ", Company", )))), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced that it received £2.3 million (approximately $2.9 million) as a research &amp; development (R&amp;D) tax credit from HMRC, the tax agency of the United Kingdom government. The tax credit is based on R&amp;D costs incurred in the year ended December 31, 2023. The Company expects to receive an additional approximately $0.8 million following confirmation of a change in the rate of tax credit regarding 2023 expenditures. &nbsp;
"The R&amp;D tax credit has been an important source of non-dilutive capital supporting Cyclacel's programs. We appreciate this governmental support as we evaluate potential precision medicine approaches for both our clinical candidates, oral fadraciclib&nbsp;and oral plogosertib, to address oncology indications with large unmet medical needs," said Paul McBarron, Executive Vice President, Finance &amp; Chief Operating Officer.

Cyclacel Pharmaceuticals Announces Receipt Of $2.9M R&D Tax Credit

<h3>Gainers</h3>
<ul>
<li>Atreca (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCEL#NASDAQ">BCEL</a>) stock rose 52.7% to $0.36 during Monday's regular session. The market value of their outstanding shares is at $14.1 million. </li>
<li>Cyclo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTH#NASDAQ">CYTH</a>) shares rose 29.51% to $1.86. The market value of their outstanding shares is at $53.3 million. </li>
<li>Elevation Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELEV#NASDAQ">ELEV</a>) stock moved upwards by 27.35% to $2.7. The market value of their outstanding shares is at $114.5 million. </li>
<li>Y-mAbs Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YMAB#NASDAQ">YMAB</a>) shares rose 27.29% to $9.59. The market value of their outstanding shares is at $418.1 million. </li>
<li>Cadrenal Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVKD#NASDAQ">CVKD</a>) stock rose 22.46% to $0.75. The market value of their outstanding shares is at $9.7 million. </li>
<li>ASLAN Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASLN#NASDAQ">ASLN</a>) shares rose 19.21% to $0.94. The market value of their outstanding shares is at $15.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>MAIA Biotechnology (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MAIA#AMEX">MAIA</a>) shares declined by 22.0% to $1.1 during Monday's regular session. The market value of their outstanding shares is at $18.6 million. </li>
<li>Sonoma Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNOA#NASDAQ">SNOA</a>) shares decreased by 20.86% to $0.18. The market value of their outstanding shares is at $2.5 million. </li>
<li>Ekso Bionics Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EKSO#NASDAQ">EKSO</a>) stock declined by 16.51% to $1.67. The market value of their outstanding shares is at $23.7 million. </li>
<li>Avalo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVTX#NASDAQ">AVTX</a>) stock fell 15.43% to $5.81. The company's market cap stands at $4.6 million. </li>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) shares fell 15.11% to $2.36. The company's market cap stands at $2.4 million. </li>
<li>Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) stock fell 14.5% to $1.18. The market value of their outstanding shares is at $6.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ASLN

AVTX

BCEL

CVKD

CYTH

EKSO

MAIA

SNOA

YMAB

12 Health Care Stocks Moving In Monday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>Akso Health Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AHG#NASDAQ">AHG</a>) shares increased by 29.2% to $1.15 during Friday's regular session. The market value of their outstanding shares is at $26.2 million. </li>
<li>Elevation Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELEV#NASDAQ">ELEV</a>) stock increased by 28.3% to $2.72. The company's market cap stands at $115.3 million. </li>
<li>Y-mAbs Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YMAB#NASDAQ">YMAB</a>) stock rose 26.69% to $9.54. The company's market cap stands at $416.1 million. </li>
<li>Atreca (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCEL#NASDAQ">BCEL</a>) stock rose 22.95% to $0.29. The company's market cap stands at $11.3 million. </li>
<li>Alaunos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCRT#NASDAQ">TCRT</a>) stock increased by 20.14% to $0.17. The company's market cap stands at $40.7 million. </li>
<li>ASLAN Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASLN#NASDAQ">ASLN</a>) shares increased by 13.77% to $0.9. The company's market cap stands at $14.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) stock decreased by 19.4% to $2.24 during Friday's regular session. The company's market cap stands at $2.2 million. </li>
<li>NexImmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEXI#NASDAQ">NEXI</a>) stock decreased by 17.97% to $9.59. The company's market cap stands at $10.1 million. </li>
<li>MAIA Biotechnology (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MAIA#AMEX">MAIA</a>) stock declined by 16.32% to $1.18. The company's market cap stands at $20.0 million. </li>
<li>Avalo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVTX#NASDAQ">AVTX</a>) shares declined by 14.56% to $5.87. The market value of their outstanding shares is at $4.7 million. </li>
<li>GeneDx Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGS#NASDAQ">WGS</a>) stock declined by 12.34% to $3.34. The company's market cap stands at $86.4 million. </li>
<li>Seelos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEEL#NASDAQ">SEEL</a>) shares decreased by 12.27% to $1.43. The company's market cap stands at $14.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SEEL

TCRT

12 Health Care Stocks Moving In Friday's Intraday Session

Shares of Juniper Networks, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/jnpr#NYSE">JNPR</a>) rose sharply in pre-market trading on Tuesday.
Hewlett Packard Enterprise Co (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hpe#NYSE">HPE</a>) is reportedly in advanced discussions to acquire networking equipment competitor Juniper Networks.
Juniper Networks shares climbed 23.3% to $37.26 in pre-market trading.
Here are some other stocks moving in pre-market trading.
<h3>Gainers</h3>
<ul>
<li>Syra Health Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/syra#NASDAQ">SYRA</a>) shares rose 56.2% to $1.89 in pre-market trading after jumping 13% on Monday.</li>
<li>Notable Labs, Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ntbl#NASDAQ">NTBL</a>) shares rose 34.4% to $1.83 in pre-market trading.</li>
<li>Galera Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/grtx#NASDAQ">GRTX</a>) surged 31.3% to $0.1959 in pre-market trading.</li>
<li>SMX (Security Matters) Public Limited Company (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/smx#NASDAQ">SMX</a>) shares climbed 13% to $0.5310 in pre-market trading after falling 8% on Monday.</li>
<li>Calidi Biotherapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cldi#NASDAQ">CLDI</a>) shares gained 12.2% to $1.75 in pre-market trading after gaining around 7% on Monday. Calidi Biotherapeutics announced the appointment of three new members to its Scientific and Medical Advisory Board.</li>
<li>CN Energy Group. Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cney#NASDAQ">CNEY</a>) shares rose 11.6% to $0.0625 in pre-market trading.</li>
<li>Top KingWin Ltd (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tcjh#NASDAQ">TCJH</a>) gained 11.1% to $1.30 in pre-market trading after dipping 39% on Monday.</li>
<li>ARB IOT Group Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/arbb#NASDAQ">ARBB</a>) gained 10.4% to $1.69 in pre-market trading.</li>
<li>MGO Global, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mgol#NASDAQ">MGOL</a>) gained 8% to $0.6339 in pre-market trading after surging 25% on Monday.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>Grifols, S.A. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/grfs#NASDAQ">GRFS</a>) shares fell 46.3% to $5.98 in pre-market trading.</li>
<li>Spectaire Holdings Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/spec#NASDAQ">SPEC</a>) shares fell 17.2% to $1.93 in pre-market trading after surging 38% on Monday.</li>
<li>Soligenix, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sngx#NASDAQ">SNGX</a>) shares fell 11.3% to $0.8328 in pre-market trading. Soligenix shares gained around 16% on Monday after the company announced that the FDA granted the company&#39;s SGX945 development program for the treatment of Behcet&#39;s Disease a &quot;Fast-Track&quot; designation.</li>
<li>Canoo Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/goev#NASDAQ">GOEV</a>) shares fell 11.1% to $0.2240 in pre-market trading. Canoo shares gained around 6% on Monday after the company announced the purchase of manufacturing assets &quot;at dramatically reduced prices&quot; to scale production at its Oklahoma City facility.</li>
<li>Bit Brother Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bets#NASDAQ">BETS</a>) shares fell 10.7% to $0.0058 in pre-market trading after dipping 15% on Monday. Bit Brother announced a 1-for-1,000 reverse share split.</li>
<li>Cyclacel Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cycc#NASDAQ">CYCC</a>) shares fell 10.4% to $2.86 in pre-market trading after jumping 28% on Monday. The company announced it regained compliance with the Nasdaq minimum bid price requirement.</li>
<li>Vincerx Pharma, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vinc#NASDAQ">VINC</a>) fell 8.8% to $1.24 in pre-market trading. Vincerx Pharma shares jumped 14% on Monday after the company released clinical results from a Phase 1 NIH-sponsored study of enitociclib in combination with venetoclax and prednisone for relapsed/refractory lymphoma.</li>
<li>Hewlett Packard Enterprise Company (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hpe#NYSE">HPE</a>) fell 8.5% to $16.21 in pre-market trading. HP might be on the verge of acquiring Juniper Networks, in a deal possibly worth around $13 billion. The announcement could be made as early as this week, according to The Wall Street Journal.</li>
<li>Zoomcar Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/zcar#NASDAQ">ZCAR</a>) shares declined 8.1% to $3.65 in pre-market trading after falling around 6% on Monday.</li>
<li>QuantaSing Group Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/qsg#NASDAQ">QSG</a>) shares fell 8% to $1.84 in pre-market trading after jumping over 27% on Monday.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/01/36550052/td-synnex-albertsons-and-3-stocks-to-watch-heading-into-tuesday"> TD SYNNEX, Albertsons And 3 Stocks To Watch Heading Into Tuesday</a>

<h3>Gainers</h3>
<ul>
<li>Aura Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AURA#NASDAQ">AURA</a>) stock moved upwards by 44.3% to $13.0 during Tuesday's pre-market session. The company's market cap stands at $640.3 million. </li>
<li>Galera Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRTX#NASDAQ">GRTX</a>) shares rose 40.01% to $0.21. The company's market cap stands at $11.3 million. </li>
<li>Jin Medical International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZJYL#NASDAQ">ZJYL</a>) stock moved upwards by 31.99% to $120.0. The company's market cap stands at $930.0 million. </li>
<li>Seres Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) stock moved upwards by 26.91% to $1.98. The company's market cap stands at $255.9 million. </li>
<li>Lucy Scientific Discovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSDI#NASDAQ">LSDI</a>) shares moved upwards by 22.83% to $0.24. The company's market cap stands at $4.2 million. </li>
<li>Elicio Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELTX#NASDAQ">ELTX</a>) shares increased by 22.37% to $9.57. The market value of their outstanding shares is at $91.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Grifols (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRFS#NASDAQ">GRFS</a>) shares declined by 35.2% to $7.21 during Tuesday's pre-market session. The company's market cap stands at $4.8 billion. </li>
<li>eFFECTOR Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EFTR#NASDAQ">EFTR</a>) stock fell 19.26% to $0.45. The company's market cap stands at $28.8 million. </li>
<li>Trevena (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRVN#NASDAQ">TRVN</a>) stock decreased by 10.25% to $0.66. The market value of their outstanding shares is at $10.0 million. </li>
<li>Apollomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLM#NASDAQ">APLM</a>) shares fell 10.05% to $0.84. The market value of their outstanding shares is at $74.8 million. </li>
<li>Societal CDMO (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCTL#NASDAQ">SCTL</a>) stock decreased by 9.19% to $0.34. The market value of their outstanding shares is at $36.1 million. </li>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) shares decreased by 8.47% to $2.92. The company's market cap stands at $2.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.